See more : Shenzhen Highpower Technology Co., Ltd. (001283.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of NanoViricides, Inc. (NNVC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NanoViricides, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Revivegen Co., Ltd. (7578.TWO) Income Statement Analysis – Financial Results
- Gungnir Resources Inc. (ASWRF) Income Statement Analysis – Financial Results
- Huayu Expressway Group Limited (1823.HK) Income Statement Analysis – Financial Results
- Xin Yuan Enterprises Group Limited (1748.HK) Income Statement Analysis – Financial Results
- Toyo Tanso Co., Ltd. (5310.T) Income Statement Analysis – Financial Results
NanoViricides, Inc. (NNVC)
About NanoViricides, Inc.
NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Human Coronavirus Program for COVID-19 seasonal coronavirus affliction; HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide, an escape-resistant anti-HIV nanoviricide. In addition, it develops other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 759.01K | 747.53K | 723.33K | 704.54K | 699.72K | 695.91K | 680.06K | 662.95K | 659.55K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -759.01K | -747.53K | -723.33K | -704.54K | -699.72K | -695.91K | -680.06K | -662.95K | -659.55K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 5.44M | 6.39M | 5.78M | 6.11M | 4.70M | 5.92M | 4.83M | 5.53M | 5.03M | 3.66M | 5.13M | 4.29M | 4.27M | 4.16M | 3.20M | 1.73M | 839.24K | 731.81K | 899.89K | 30.77K |
| General & Administrative | 3.08M | 2.55M | 2.33M | 2.63M | 3.30M | 2.74M | 4.50M | 4.07M | 3.83M | 3.40M | 3.54M | 2.30M | 1.82M | 2.27M | 1.74M | 1.09M | 1.95M | 2.35M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 3.08M | 2.55M | 2.33M | 2.63M | 3.30M | 2.74M | 4.50M | 4.07M | 3.83M | 3.40M | 3.54M | 2.30M | 1.82M | 2.27M | 1.74M | 1.09M | 1.95M | 2.35M | 1.70M | 35.23K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | -142.67K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 8.52M | 8.94M | 8.11M | 8.74M | 8.00M | 8.66M | 9.33M | 9.60M | 8.86M | 7.06M | 8.67M | 6.59M | 6.08M | 6.43M | 4.94M | 2.82M | 2.79M | 3.08M | 2.60M | 66.01K |
| Cost & Expenses | 8.52M | 8.94M | 8.11M | 8.74M | 8.00M | 8.66M | 9.33M | 9.60M | 8.86M | 7.06M | 8.67M | 6.59M | 6.08M | 6.43M | 4.94M | 2.82M | 2.79M | 3.08M | 2.60M | 66.01K |
| Interest Income | 221.97K | 355.83K | 11.86K | 9.35K | 17.08K | 55.50K | 100.43K | 60.96K | 62.64K | 160.86K | 171.00K | 55.59K | 46.79K | 14.34K | 0.00 | 31.93K | 0.00 | 54.51K | 0.00 | 0.00 |
| Interest Expense | 0.00 | 938.00 | 5.12K | 85.41K | 93.67K | 0.00 | 544.49K | 2.13M | 2.47M | 3.82M | 3.66M | 1.09M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 90.56K | 0.00 | 0.00 |
| Depreciation & Amortization | 759.01K | 747.53K | 723.33K | 704.54K | 699.72K | 695.91K | 680.06K | 662.95K | 659.55K | 302.74K | 212.01K | 219.65K | 219.65K | 527.74K | 90.29K | 12.29K | 13.47K | 36.30K | 44.56K | 0.00 |
| EBITDA | -7.76M | -7.84M | -7.38M | -8.03M | -7.30M | -7.96M | -8.59M | -8.94M | -8.20M | -6.76M | -8.46M | -7.56M | -5.99M | -5.95M | -4.65M | -2.83M | -2.73M | -3.03M | -2.55M | -66.01K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -8.52M | -8.94M | -8.11M | -8.74M | -8.00M | -8.66M | -9.33M | -9.60M | -8.86M | -7.06M | -8.67M | -6.59M | -6.08M | -6.43M | -4.94M | -2.82M | -2.79M | -3.08M | -2.60M | -66.01K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 221.97K | 354.90K | 6.74K | -78.08K | -5.45M | 235.24K | 761.71K | -703.77K | -1.87M | 4.86M | -4.93M | -2.29M | -125.46K | -47.71K | 358.27K | -26.20K | 53.70K | -36.05K | -688.58K | 0.00 |
| Income Before Tax | -8.29M | -8.59M | -8.11M | -8.82M | -13.45M | -8.42M | -8.56M | -10.30M | -10.72M | -2.20M | -14.11M | -8.88M | -6.21M | -6.48M | -4.74M | -2,787.80B | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 355.83K | -6.74K | 85.41K | -49.00K | -179.75K | 1.31M | 2.13M | 2.47M | 3.82M | 3.66M | 1.09M | 125.46K | 47.71K | -195.74K | 31.93B | -53.70K | 36.05K | 688.58K | 66.01K |
| Net Income | -8.29M | -8.59M | -8.10M | -8.91M | -13.40M | -8.24M | -8.56M | -10.30M | -10.72M | -2.20M | -14.11M | -8.88M | -6.21M | -6.48M | -4.74M | -2.79M | -2.74M | -3.12M | -3.28M | -66.01K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.70 | -0.74 | -0.70 | -0.82 | -2.39 | -2.30 | -2.64 | -3.43 | -3.72 | -0.78 | -5.51 | -3.87 | -2.90 | -3.26 | -2.54 | -1.63 | -1.64 | -1.94 | -2.22 | -0.05 |
| EPS Diluted | -0.70 | -0.74 | -0.70 | -0.82 | -2.39 | -2.30 | -2.64 | -3.43 | -3.72 | -0.74 | -5.51 | -3.73 | -2.90 | -3.26 | -2.54 | -1.63 | -1.64 | -1.94 | -2.22 | -0.05 |
| Weighted Avg Shares Out | 11.87M | 11.63M | 11.53M | 10.90M | 5.62M | 3.59M | 3.25M | 3.01M | 2.88M | 2.83M | 2.56M | 2.29M | 2.14M | 1.99M | 1.86M | 1.71M | 1.67M | 1.60M | 1.48M | 1.43M |
| Weighted Avg Shares Out (Dil) | 11.87M | 11.63M | 11.53M | 10.90M | 5.62M | 3.59M | 3.25M | 3.01M | 2.88M | 2.96M | 2.56M | 2.38M | 2.14M | 1.99M | 1.86M | 1.71M | 1.67M | 1.60M | 1.48M | 1.43M |
NanoViricides CEO highlights urgency of H5N1 preparedness as cases rise in North America
The rise of unexplained human cases of bird flu in North America means there is an urgent need for effective treatments that can withstand viral mutations. In this opinion article, Anil Diwan, CEO of NanoViricides (NYSE-A:NNVC), a clinical-stage nano-biopharmaceutical company...
NanoViricides pushes NV-387 to Phase II trials
NanoViricides (NYSE-A:NNVC) reported progress on its lead antiviral drug NV-387 and revealed plans to advance Phase II clinical trials for MPox and RSV. The Shelton, Connecticut-based company is waiting for results from its Phase I trial of NV-387 and has...
NanoViricides, Inc. Has Filed Its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID
SHELTON, CT / ACCESSWIRE / November 15, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the quarter ending September 30, 2024 with the Securities and Exchange Commission (SEC)...
NanoViricides to Provide Corporate Update at the Spartan Capital Investors Conference 2024, Today at 9:45am
SHELTON, CT / ACCESSWIRE / November 4, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, today announces that Anil R. Diwan, Ph.D.
NanoViricides President Dr. Diwan Interviwed in PODD Podcast; He Explains the Revolutionary Clinical Stage Broad-Spectrum Antiviral NV-387, and the Potential of the Platform to Revolutionize Fields Beyond Virology
SHELTON, CT / ACCESSWIRE / October 15, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, today announces that Anil R. Diwan, Ph.D.
NanoViricides to Present at the Global AMR Summit 2024 Tomorrow
Dr. Diwan to Discuss "Shape-Shifting", "Trojan Horse", Pathogen-Directed Attack Capability of NanoViricides Platform Technology to Combat AMR SHELTON, CT / ACCESSWIRE / October 8, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral...
NanoViricides prepares for Phase II trials for antiviral NV-387
NanoViricides (NYSE-A:NNVC) filed its annual report, announcing that its broad-spectrum antiviral NV-387 is progressing to Phase II clinical trials, with potential indications including RSV, influenza, MPOX/smallpox, and COVID-19. NV-387 has demonstrated broad-spectrum efficacy in preclinical trials against viruses such as...
NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include RSV, Influenza, MPOX/Smallpox, COVID
SHELTON, CT / ACCESSWIRE / September 30, 2024 / NanoViricides, Inc. (NYSE American:NNVC ) (the "Company"), reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June 30, 2024 with the Securities and Exchange...
NanoViricides expands antiviral drug pipeline with TheraCour Pharma agreement
NanoViricides (NYSE-A:NNVC) announced that it has signed a Memorandum of Understanding (MOU) with TheraCour Pharma, granting it the right of first refusal on all antiviral drug developments. This agreement expands NanoViricides (NYSE-A:NNVC)' access to critical intellectual property, enhancing its ability...
NanoViricides Executes an Agreement Encompassing All Antiviral Drug Treatments With Theracour, Including “Trojan Horse” Drugs
SHELTON, CT / ACCESSWIRE / September 26, 2024 / NanoViricides, Inc. (NYSE American.: NNVC ) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, reports today that it has now obtained a right of first refusal (ROFR) for...
Source: https://incomestatements.info
Category: Stock Reports